Ramsay Health (ASX:RHC) share price presents a reopening play: Fund manager

Could Ramsay Health make for a reopening investment? This fundie believes so…

| More on:
A woman opens and reaches into a big cardboard box, with a big smile on her face.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Ramsay Health Care Limited (ASX: RHC) share price has been an underperformer over the past year. During the last 12 months, shares in the healthcare facility operator have traded sideways, gaining ~2%. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has dished out a 23.7% return to investors over the same period.

Although, one fund manager is betting on the tide turning as COVID-19 restrictions ease across its operating geographies.

Let's take a look at why Sydney-based Perennial Partners are bullish on the Ramsay Health share price.

A big backlog filtering through

Firstly, the Perennial Value Australian Shares Trust invests in a broad swathe of ASX shares, with the aim of outperforming the S&P/ASX 300 Accumulation Index on a rolling 3-year basis. At the end of August, the trust held $761 million in funds under management.

To outperform the index, the fund must attempt to balance its investment weightings better than the index itself. As such, compared to the index, the Perennial Value fund is underweight on Rio Tinto Limited (ASX: RIO), Transurban Group (ASX: TCL), Goodman Group (ASX: GMG), Australia and New Zealand Banking Group Ltd (ASX: ANZ), and Afterpay Ltd (ASX: APT).

On the contrary, there are several ASX-listed companies in which the fund sees greater upside potential. One of these shares is Ramsay Health Care. As a result, the Perennial Value fund is overweight with Ramsay when comparing to its benchmark index.

In the near term, elective surgery restrictions in Australia are impacting the healthcare company's earnings. However, looking beyond this, the fund points out a likely bounce back in surgical volumes once restrictions lift.

Providing justification, Perennial drew attention to the increase in volumes in Ramsay's United Kingdom operations. Considering the UK is largely open again, procedures deferred by COVID-19 are now being tended to.

According to the Australian Institute of Health and Welfare, the median waiting time for elective surgery in Australia for 2019-2020 increased to 77 days from 66 days. On a similar note, The Age recently reported a significant blowout in Victoria's hospital waiting lists.

Specifically, the state's elective surgery waiting list has reached more than 65,000 people – with more than 30,000 procedures being cancelled last year.

Positioning for upside in Ramsay Health share price

The Perennial fund is putting its (investors') money where its mouth is. According to the trust's activity in August, the fund took profits in some of its outperforming holdings and redirected that capital elsewhere.

In gearing up for a reopening boom, Perennial allocated those proceeds to several ASX shares, including Ramsay Health.

The Ramsay Health share price finished the Monday trading session at $69.28.

Motley Fool contributor Mitchell Lawler owns shares of AFTERPAY T FPO and Ramsay Health Care Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »